MedTrace Logo

Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects

NCT00497458 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-04-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)

Conditions

Interventions

DRUG

Testosterone

testosterone 40 or 80 mg once a day

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Havah Therapeutics Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Stephen N Birrell, MD PhD · Havah Therapeutics Pty Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-04-30
Completion
2009-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497458 on ClinicalTrials.gov